Table 2. Association between VEGFA polymorphisms and sunitinib outcome in mRCC.
| Gene SNPs | First author, year | Allele/Genotype | PFS HR (95% CI) | P value | OS HR (95% CI) | P value | Analysis method |
|---|---|---|---|---|---|---|---|
| VEGFA rs2010963(G>C) | Dornbusch, 2016 | CC+CG vs GG | 0.615 (0.357–1.061) M 0.683 (0.463–1.008) U | 0.08 M 0.055 U | 0.751 (0.354–1.593) M 0.687 (0.403–1.173) U | 0.455 M 0.169 U | M/U |
| Scartozzi, 2013 | CG vs GG | 3.34 (1.19–9.38) U | < 0.05 U | NA | NA | M | |
| Scartozzi, 2013 | CC vs GG | 15.77 (3.11–79.92) U | < 0.05U | NA | NA | M | |
| Garcia-Donas, 2011 | CC vs GG | 0.96 (0.62–1.49) M | 0.86 | 1.08 (0.59–1.96) M | 0.8 | M | |
| VEGFA rs699947 (A>C) | Dornbusch, 2016 | CC+AC vs AA | 1.029 (0.496–2.135) M 0.535 (0.317–0.904) U | 0.939 M 0.019 U | 0.626 (0.256–1.531) M 0.614 (0.316–1.192) U | 0.304 M 0.149 U | M/U |
| Garcia-Donas, 2011 | CC vs AA | 1.01 (0.68–1.51) M | 0.96 M | 0.72 (0.40–1.27) M | 0.25 M | M | |
| VEGFA rs1570360 (G>A) | Dornbusch, 2016 | AA+AG vs GG | 0.981 (0.616–1.563) M 1.087 (0.741–1.595) U | 0.936 M 0.670 U | 0.757 (0.406–1.410) M 0.884 (0.520–1.502) U | 0.380 M 0.649 U | M/U |
| Garcia-Donas, 2011 | AA vs GG | 1.13 (0.75–1.70) M | 0.56 M | 0.79 (0.44–1.44) M | 0.44 M | M |
The source of HR and 95% CI was extracted from survival curves or article reports.
HRs, hazard ratios; 95% CI, 95% confidence interval; M, multivariate analysis; U, univariate analysis.
SNPs, single-nucleotide polymorphisms; VEGFA, vascular endothelial growth factor A; VEGFR, vascular endothelial growth factor receptor; OS, overall survival; PFS, progression-free survival.